Which systemic therapies good at improving index scores in moderate-to-severe atopic dermatitis?

A new meta analysis showed that Upadacitinib, 30 mg daily, and abrocitinib, 200 mg daily, were linked with somewhat better ratings than dupilumab, whereas upadacitinib, 15 mg daily showed similar scores as dupilumab in terms of safety in atopic dermatitis.

The findings of this study were published in the Journal of American Medical Association - Dermatology.

Systemic therapies for atopic dermatitis are largely examined in placebo-based trials; network meta-analysis can offer estimates of relative effectiveness and safety for treatments that have not been compared head to head. As a result, Aaron M. Drucker and his colleagues did this research. A live comprehensive review and network meta-analysis were conducted to evaluate claimed effectiveness and safety measures in clinical trials of systemic therapies for atopic dermatitis.

This investigation searched the Cochrane Central Register of Controlled Trials, Embase, MEDLINE, Latin American and Caribbean Health Science Information database, Global Resource of EczemA Trials database, and trial registries until June 15, 2021. After reviewing titles, abstracts, and publications in triplicate, randomized clinical studies assessing 8 or more weeks of therapy with systemic immunomodulatory drugs for moderate-to-severe atopic dermatitis were included. Data was collected in duplicate. Bayesian network meta-analyses were done, as well as assessments of the Grading of Recommendations Assessment, Development, and Evaluation certainty of evidence. From June to December 2021, the new analysis was done.